

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

1. (currently amended): An agent for the ~~prevention or~~ treatment of a disease associated with hyperglycemia, comprising as an active ingredient ~~ana-selective~~ SGLT1 inhibitor wherein the active ingredient and/or its metabolite exhibit an SGLT1 inhibitory effect substantially showing no GLUT2 and/or GLUT5 inhibitory effect.
2. (currently amended): An agent for the ~~prevention or~~ treatment as claimed in claim 1, wherein the active ingredient and/or its metabolite exhibit an SGLT1 inhibitory effect substantially showing no inhibitory effect on absorbing fructose through the small intestine is an SGLT1 inhibitor substantially showing no GLUT2 and/or GLUT5 inhibitory effect.
3. (currently amended): An agent for the ~~prevention or~~ treatment as claimed in claim 1, wherein the dosage form is an oral agent.
4. (currently amended): An agent for the ~~prevention or~~ treatment as claimed in claim 1, wherein the disease associated with hyperglycemia is diabetes.
5. (currently amended): An agent for the ~~prevention or~~ treatment as claimed in claim 4, wherein the diabetes is postprandial hyperglycemia.

6. (currently amended): An agent for the ~~prevention or~~ treatment as claimed in claim 1, wherein the disease associated with hyperglycemia is impaired glucose tolerance.

7. (currently amended): An agent for the ~~prevention or~~ treatment as claimed in claim 1, wherein the disease associated with hyperglycemia is diabetic complications.

8. (currently amended): An agent for the ~~prevention or~~ treatment as claimed in claim 1, wherein the disease associated with hyperglycemia is obesity.

9. (currently amended): A method for the ~~prevention or~~ treatment of a disease associated with hyperglycemia, which comprises administering an effective amount of ~~ana~~ selective SGLT1 inhibitor wherein the active ingredient and/or its metabolite exhibit an SGLT1 inhibitory effect substantially showing no GLUT2 and/or GLUT5 inhibitory effect.

10. (currently amended): A method for the ~~prevention or~~ treatment as claimed in claim 9, wherein the active ingredient and/or its metabolite exhibit an SGLT1 inhibitory effect substantially showing no inhibitory effect on absorbing fructose through the small intestines~~selective SGLT1 inhibitor is an SGLT1-inhibitor substantially showing no GLUT2 and/or GLUT5 inhibitory effect.~~

11. (currently amended): A method for the ~~prevention or~~ treatment as claimed in claim 9, wherein the dosage form is an oral agent.

12. (currently amended): A method for the ~~prevention or~~ treatment as claimed in claim 9, wherein the disease associated with hyperglycemia is diabetes.

13. (currently amended): A method for the ~~prevention or~~ treatment as claimed in claim 12, wherein the diabetes is postprandial hyperglycemia.

14. (currently amended): A method for the ~~prevention or~~ treatment as claimed in claim 9, wherein the disease associated with hyperglycemia is impaired glucose tolerance.

15. (currently amended): A method for the ~~prevention or~~ treatment as claimed in claim 9, wherein the disease associated with hyperglycemia is diabetic complications.

16. (currently amended): A method for the ~~prevention or~~ treatment as claimed in claim 9, wherein the disease associated with hyperglycemia is obesity;

17. (currently amended): A method for the manufacture of a pharmaceutical composition for the ~~prevention or~~ treatment of a disease associated with hyperglycemia, which method comprises blending the ~~selective~~ SGLT1 inhibitor of claim 1 with a pharmaceutically acceptable additive.

18. (currently amended): A method as claimed in claim 17, wherein the ~~selective~~ SGLT1 inhibitor is an SGLT1 inhibitor substantially showing no inhibitory effect on absorbing fructose through the small intestine ~~GLUT2 and/or GLUT5 inhibitory effect~~.

19. (currently amended): A method as claimed in claim 17, wherein the composition is an oral agent.

20. (currently amended): A method as claimed in claim 17, wherein the disease associated with hyperglycemia is diabetes. .

21. (currently amended): A method as claimed in claim 20, wherein the diabetes is postprandial hyperglycemia.

22. (currently amended): A method as claimed in claim 17, wherein the disease associated with hyperglycemia is impaired glucose tolerance.

23. (currently amended): A method as claimed in claim 17, wherein the disease associated with hyperglycemia is diabetic complications.

24. (currently amended): A method as claimed in claim 17, wherein the disease associated with hyperglycemia is obesity.

25. (currently amended): An agent for the ~~prevention or~~ treatment as claimed in claim 2, wherein the dosage form is an oral agent.

26. (currently amended): An agent for the ~~prevention or~~ treatment as claimed in claim 2, wherein the disease associated with hyperglycemia is diabetes.

27. (currently amended): An agent for the ~~prevention or~~ treatment as claimed in claim 3, wherein the disease associated with hyperglycemia is diabetes.

28. (currently amended): An agent for the ~~prevention or~~ treatment as claimed in claim 2, wherein the disease associated with hyperglycemia is impaired glucose tolerance.

29. (currently amended): An agent for the ~~prevention or~~ treatment as claimed in claim 3, wherein the disease associated with hyperglycemia is impaired glucose tolerance.

30. (currently amended): An agent for the ~~prevention or~~ treatment as claimed in claim 2, wherein the disease associated with hyperglycemia is diabetic complications.

31. (currently amended): An agent for the ~~prevention or~~ treatment as claimed in claim 3, wherein the disease associated with hyperglycemia is diabetic complications.

32. (currently amended): An agent for the ~~prevention or~~ treatment as claimed in claim 2, wherein the disease associated with hyperglycemia is obesity.

33. (currently amended): An agent for the ~~prevention or~~ treatment as claimed in claim 3, wherein the disease associated with hyperglycemia is obesity.

34. (currently amended): A method for the ~~prevention or~~ treatment as claimed in claim 10, wherein the dosage form is an oral agent.

35. (currently amended): A method for the ~~prevention or~~ treatment as claimed in claim 10, wherein the disease associated with hyperglycemia is diabetes.

36. (currently amended): A method for the ~~prevention or~~ treatment as claimed in claim 11, wherein the disease associated with hyperglycemia is diabetes.

37. (currently amended): A method for the ~~prevention or~~ treatment as claimed in claim 10, wherein the disease associated with hyperglycemia is impaired glucose tolerance.

38. (currently amended): A method for the ~~prevention or~~ treatment as claimed in claim 11, wherein the disease associated with hyperglycemia is impaired glucose tolerance.

39. (currently amended): A method for the ~~prevention or~~ treatment as claimed in claim 10, wherein the disease associated with hyperglycemia is diabetic complications.

40. (currently amended): A method for the ~~prevention or~~ treatment as claimed in claim 11, wherein the disease associated with hyperglycemia is diabetic complications.

41. (currently amended): A method for the ~~prevention or~~ treatment as claimed in claim 10, wherein the disease associated with hyperglycemia is obesity.

42. (currently amended): A method for the ~~prevention or~~ treatment as claimed in claim 11, wherein the disease associated with hyperglycemia is obesity;

43. (previously presented): A method as claimed in claim 18, wherein the composition is an oral agent.

44. (previously presented): A method as claimed in claim 18, wherein the disease associated with hyperglycemia is diabetes.

45. (previously presented): A method as claimed in claim 19, wherein the disease associated with hyperglycemia is diabetes.

46. (previously presented): A method as claimed in claim 18, wherein the disease associated with hyperglycemia is impaired glucose tolerance.

47. (previously presented): A method as claimed in claim 19, wherein the disease associated with hyperglycemia is impaired glucose tolerance.

48. (previously presented): A method as claimed in claim 18, wherein the disease associated with hyperglycemia is diabetic complications.

49. (previously presented): A method as claimed in claim 19, wherein the disease associated with hyperglycemia is diabetic complications.

50. (currently amended): A ~~method~~use as claimed in claim 18, wherein the disease associated with hyperglycemia is obesity.

51. (previously presented): A method as claimed in claim 19, wherein the disease associated with hyperglycemia is obesity.